Technology
The Problem
Conventional manufacturing technology is scaled for mass production at large volumes. This results in a process that is labor intensive, high cost per batch, and highly wasteful. Additionally, there is a long turnaround time from production and testing to releasing and shipping the final product. This lends current biologics manufacturing to favor far-reaching diseases where larger volume costs are justified.
The Opportunity
Small batch manufacturing resolves these pain points and captures emerging demand for therapeutics at a smaller scale and lower cost. The need exists to manufacture at lower volumes for targeted therapies in rare diseases not suited for mass production which in turn drives precision medicine forward. Academic medical centers, biologics drug sponsors and contract manufacturing will benefit from this opportunity becoming reality.
Our Solution
We are developing an automated benchtop system for small scale biologics manufacturing with our proprietary technology. This end-to-end solution provides:
- Decreased batch costs
- Decreased turnaround time
- Reduced manual labor
- Reduced supply chain complexity
- Increased access to targeted therapies in diseases where there is currently no option